Journal article
Interferon-free combination therapies for the treatment of hepatitis C: current insights
Jacinta A Holmes, Alexander J Thompson
HEPATIC MEDICINE-EVIDENCE AND RESEARCH | DOVE MEDICAL PRESS LTD | Published : 2015
DOI: 10.2147/HMER.S55864
Open access
Abstract
The hepatitis C virus (HCV) treatment landscape has rapidly changed over the past 5 years. The development of direct-acting antiviral (DAA) agents that specifically target various steps in the HCV lifecycle has revolutionized therapeutic options for patients with HCV, with the development of highly effective and well-tolerated oral interferon-free regimens. There are many DAAs that are currently in development or have recently been approved, which target different nonstructural HCV proteins and host targets that are essential for HCV replication. This review will focus on the different classes of DAAs and the various combinations that are in advanced development for the treatment of chronic ..
View full abstractGrants
Funding Acknowledgements
JAH received GESA postgraduate scholarship and research/grant support from Roche and Merck; AJT was the coinventor of a patent related to the IFNL3/IL28B discovery and received research/grant support from Merck, Roche, Gilead Sciences, consulting advisory fees from Merck, Roche, Janssen, Bristol-Myers Squibb, GlaxoSmithKline, Novartis, and Springbank, and speaker fees from Merck, Roche, Gilead Sciences, Bristol-Myers Squibb, and Janssen.